Drug-induced idiosyncratic hepatotoxicity: Prevention strategy developed after the troglitazone case

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 1, 2011, Pages 60-70

  Ikeda, Toshihiko ^a  

^a YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

Chemically reactive metabolite; Drug induced liver injury; Idiosyncratic drug reactions; Prevention; Troglitazone

Indexed keywords

ABACAVIR; ALLOPURINOL; BIOLOGICAL MARKER; CARBAMAZEPINE; CHROMAN DERIVATIVE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; ENZYME ANTIBODY; FLUCLOXACILLIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; ISOENZYME; PARACETAMOL; QUINONE DERIVATIVE; SEMIQUINONE; SULFENIC ACID DERIVATIVE; THIAZOLIDINE DERIVATIVE; TICLOPIDINE; TROGLITAZONE;

APOPTOSIS; COVALENT BOND; DRUG CONTRAINDICATION; DRUG DEGRADATION; DRUG DEVELOPMENT; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMMUNOPATHOLOGY; IN VITRO STUDY; LIVER CELL DAMAGE; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN ALLERGY; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; VIRUS HEPATITIS;

EID: 79952764705     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RV-090     Document Type: Review

References (62)

1. Kuramoto, K., Shimizu, N. and Toda, G.: Liver dysfunction associated with troglitazone Noscal. J. Clin. Ther. Med., 14: 461-466 1998. In Japanese.
2. Watanabe, T., Ohashi, Y., Yasuda, M., Takaoka, M., Furukawa, T., Yamoto, T., Sambuissho, A. and Manabe, S.: Was it not possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies? Reevaluation of safety. Iyakuhin Kenkyu, 30: 537-546 1999. In Japanese.
3. Yokoi, T.: Troglitazone. Handb. Exp. Pharmacol., 196: 419-435 2010.
4. Zhang, X., Liu, F., Chen, X., Zhu, X. and Uetrecht, J.: Involvement of the immune system in idiosyncratic drug reactions. Drug Metab. Pharmacokinet., 26: 47-59 2011.
5. Zimmerman, H. J.: Various forms of chemically induced liver injury and their detection by diagnostic procedures. Environ. Health Perspect., 15: 3-12 1976.
6. Maniratanachote, R., Shibata, A., Kaneko, S., Yamamori, I., Wakasugi, T., Sawazaki, T., Katoh, K., Tokudome, S., Nakajima, M. and Yokoi, T.: Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicol- ogy, 216: 15-23 2005.
7. Liu, Z. X. and Kaplowitz, N.: Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol., 2: 493-503 2006.
8. Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A. L., Davis, M. M. and Williams, R.: Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med., 303: 66-71 1980.
9. Kawai, K., Kawasaki-Tokui, Y., Odaka, T., Tsuruta, F., Kazui, M., Iwabuchi, H., Nakamura, T., Kinoshita, T., Ikeda, T., Yoshioka, T., Komai, T. and Nakamura, K.: Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung, 47: 356-368 1997.
10. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G. and Baillie, T. A.: Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol., 14: 62-70 2001.
11. Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M. and Yokoi, T.: Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos., 30: 155-160 2002.
12. He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J. and Woolf, T. F.: Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos., 32: 639-646 2004.
13. Sato, H., Dilone, E., Nangia, A., Zhao, S. and Frank, K.: Covelent adducts in human primary hepatocytes cultured with [14C]-troglitazone. Drug Metab. Rev., 32 Suppl. 2: 204 2000.
14. Gan, J., Qu, Q., He, B., Shyu, W. C., Rodrigues, A. D. and He, K.: Troglitazone thiol adduct formation in human liver micro- somes: enzyme kinetics and reaction phenotyping. Drug Metab. Lett., 2: 184-189 2008.
15. Ramachandran, V., Kostrubsky, V. E., Komoroski, B. J., Zhang, S., Dorko, K., Esplen, J. E., Strom, S. C. and Venkataramanan, R.: Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos., 27: 1194-1199 1999.
16. Sahi, J., Hamilton, G., Sinz, M., Barros, S., Huang, S. M., Lesko, L. J. and LeCluyse, E. L.: Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica, 30: 273-284 2000.
17. Loi, C. M., Stern, R., Koup, J. R., Vassos, A. B., Knowlton, P. and Sedman, A. J.: Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. J. Clin. Pharmacol., 39: 410-417 1999.
18. Frantz, P. and Nguyen, T. T.: Rezulin troglitazone greatly increases cyclosporine metabolism. J. Heart Lung Transplant., 17: 1037-1038 1998.
19. Park, M. H., Pelegrin, D., Haug, M. T., III and Young, J. B.: Troglitazone, a new antidiabetic agent, decreases cyclosporine level. J. Heart Lung Transplant., 17: 1139-1140 1998.
20. Koup, J. R., Anderson, G. D. and Loi, C. M.: Effect of troglitazone on urinary excretion of 6Ç-hydroxycortisol. J. Clin. Pharmacol., 38: 815-818 1998.
21. Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., Matsushita, Y., Furukawa, H., Haruyama, H. and Koga, T.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther., 73: 435-455 2003.
22. Lucena, M. I., Andrade, R. J., Martínez, C., Ulzurrun, E., García-Martín, E., Borraz, Y., Fernández, M. C., Romero-Gomez, M., Castiella, A., Planas, R., Costa, J., Anzola, S. and Agúndez, J. A.: Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 48: 588-596 2008.
23. Okada, R., Ishizu, Y., Endo, R., Lezhava, A., Ieiri, I., Kusuhara, H., Sugiyama, Y. and Hayashizaki, Y.: Direct and rapid genotyping of glutathione-S-transferase M1 and T1 from human blood specimens using the SmartAmp2 method. title typejournalDrug Metab. Dispos., 2010 Jul 7. [Epub ahead of print]
24. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. and Chen, Y. T.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 428: 486 2004.
25. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., Yang, L. C., Hong, H. S., Chen, M. J., Lai, P. C., Wu, M. S., Chu, C. Y., Wang, K. H., Chen, C. H., Fann, C. S., Wu, J. Y. and Chen, Y. T.: HLA- B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U.S.A., 102: 4134-4139 2005.
26. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H. and Okutani, Y.: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J., 8: 29-33 2008.
27. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Peöer, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, H. J., Pirmohamed, M., Aithal, G. P. and Day, C. P.: HLA- B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 41: 816-819 2009.
28. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Information for healthcare professionals, Carbama- zepine marketed as carbatrol, equetro, tegretol, and generics, December 13 2007.
29. Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D. and Benbow, A.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med., 358: 568-579 2008.
30. Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M. and Roujeau, J. C.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J., 6: 265-268 2006.
31. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J., Furuya, H., Takahashi, Y., Muramatsu, M., Kinoshita, S., Abe, M., Ikeda, H., Kashiwagi, M., Song, Y., Ueta, M., Sotozono, C., Ikezawa, Z. and Hasegawa, R.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol- related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9: 1617-1622 2008.
32. Tohkin, M., Ishiguro, A., Kaniwa, N., Saito, Y., Kurose, K. and Hasegawa, R.: Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab. Pharmacokinet., 25: 122-133 2010.
33. Nelson, D. R., Marousis, C. G., Davis, G. L., Rice, C. M., Wong, J., Houghton, M. and Lau, J. Y.: The role of hepatitis C virus- specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol., 158: 1473-1481 1997.
34. Ando, K., Hiroishi, K., Kaneko, T., Moriyama, T., Muto, Y., Kayagaki, N., Yagita, H., Okumura, K. and Imawari, M.: Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol., 158: 5283-5291 1997.
35. Matzinger, P.: Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12: 991-1045 1994.
36. Uetrecht, J. P.: New concepts in immunology relevant to idiosyncratic drug reactions: the údanger hypothesisû and innate immune system. Chem. Res. Toxicol., 12: 387-395 1999.
37. Uetrecht, J. P.: Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol., 21: 84-92 2008.
38. Toyoda, Y., Tsuchida, A., Iwami, E. and Miwa, I.: Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci., 68: 1867-1876 2000.
39. Haskins, J. R., Rowse, P., Rahbari, R. and de la Iglesia, F. A.: Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol., 75: 425-438 2001.
40. Yamamoto, Y., Nakajima, M., Yamazaki, H. and Yokoi, T.: Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci., 70: 471-482 2001.
41. Rachek, L. I., Yuzefovych, L. V., Ledoux, S. P., Julie, N. L. and Wilson, G. L.: Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol., 240: 348-354 2009.
42. Funk, C., Ponelle, C., Scheuermann, G. and Pantze, M.: Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump Bsep in the rat. Mol. Pharmacol., 59: 627-635 2001.
43. Baillie, T. A.: Drug Metabolizing Enzymes. In Lee, J. S., Obach, R. S. and Fischer, M. B. eds.: Cytochrome P450 and Other Enzyme in Drug Discovery and Development. Lausanne, Fontis Media, Switzerland and New York, Marcel Dekker, USA 2003, pp. 147-154.
44. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. and Baillie, T. A.: Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 17: 3-16 2004.
45. Uetrecht, J.: Precition of a new drugös potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Dev., 4: 55-59 2001.
46. Naritomi, Y., Teramura, Y., Terashita, S. and Kagayama, A.: Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple metho for detecting quasi-irreversible and irreversible inhibitors. Drug Metab. Pharmacokinet., 19: 55-61 2004.
47. Yan, Z., Maher, N., Torres, R., Caldwell, G. W. and Huebert, N.: Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun. Mass Spectrom., 19: 3322-3330 2005.
48. Mutlib, A., Lam, W., Atherton, J., Chen, H., Galatsis, P. and Stolle, W.: Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites. Rapid Commun. Mass Spectrom., 19: 3482-3492 2005.
49. Dieckhaus, C. M., Fernández-Metzler, C. L., King, R., Krolikowski, P. H. and Baillie, T. A.: Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol., 18: 630-638 2005.
50. Masubuchi, N., Makino, C. and Murayama, N.: Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol., 20: 455-464 2007.
51. Takakusa, H., Masumoto, H., Makino, C., Okazaki, O. and Sudo, K.: Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab. Pharmacokinet., 24: 100-107 2009.
52. Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C. and Humphreys, W. G.: In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol., 22: 690-698 2009.
53. Chen, L. J., Hecht, S. S. and Peterson, L. A.: Characterization of amino acid and glutathione adducts of cis-2-butene-1,4-dial, a reactive metabolite of furan. Chem. Res. Toxicol., 10: 866-874 1997.
54. Meneses-Lorente, G., Sakatis, M. Z., Schulz-Utermoehl, T., De Nardi, C. and Watt, A. P.: A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal. Biochem., 51: 266-272 2006.
55. Argoti, D., Liang, L., Conteh, A., Chen, L., Bershas, D., Yu, C. P., Vouros, P. and Yang, E.: Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry LC-MS/MS. Chem. Res. Toxicol., 18: 1537-1544 2005.
56. Rousu, T., Pelkonen, O. and Tolonen, A.: Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom., 23: 843-855 2009.
57. Xu, S., Zhu, B., Teffera, Y., Pan, D. E., Caldwell, C. G., Doss, G., Stearns, R. A., Evans, D. C. and Beconi, M. G.: Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab. Dispos., 33: 121-130 2005.
58. Mitchell, M. D., Elrick, M. M., Walgren, J. L., Mueller, R. A., Morris, D. L. and Thompson, D. C.: Peptide-based in vitro assay for the detection of reactive metabolites. Chem. Res. Toxicol., 21: 859-868 2008.
59. Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O. and Sudo, K.: Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab. Dispos., 36: 1770-1779 2008.
60. Obach, R. S., Kalgutkar, A. S., Soglia, J. R. and Zhao, S. X.: Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and 62 daily dose. Chem. Res. Toxicol., 21: 1814-1822 2008.
61. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E. and Chalasani, N.: Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology, 47: 2003-2009 2008
62. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D. and Okazaki, O.: A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 37: 1970-1977 2009.